Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report

JCO Precis Oncol. 2024 Sep:8:e2400228. doi: 10.1200/PO.24.00228.

¹ Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
² Department of Medical Oncology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
³ Department of Pathology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
⁴ Department of Pathology, Okayama University Hospital, Okayama, Japan.
⁵ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁶ Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
⁷ Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Abstract

Imatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.